IP Library Granted Patent US 8,846,093
Granted Patent B2
US 8,846,093 · App. 13/100,581 · Granted Sep 30, 2014

Adhesive mixture for transdermal delivery of highly plasticizing drugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,093
App. No.
13/100,581
Granted
Sep 30, 2014
Kind
B2
Abstract

Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.

Claims (17)

1. A transdermal delivery system comprising a blend of

(a) one or more hydrophobic adhesive polymers; and

(b) a therapeutically effective amount of one or more drugs, at least one of which is of low molecular weight and liquid at or about room temperatures,

said system comprising solvents consisting essentially of at least one solvent which volatilizes during drying at a temperature of between about 100° F. and 200° F.

2. The transdermal delivery system of claim 1 wherein said solvents volatilize during drying at a temperature of between about 100° F. and 140° F.

3. The transdermal delivery system of claim 1 wherein said one or more drugs comprises one or more highly plasticizing drugs.

4. The transdermal delivery system of claim 3 wherein said highly plasticizing drugs are selected from the group consisting of selegiline, fluoxetine, des-methyl selegiline, tetracaine and chlorpheniramine.

5. The transdermal delivery system of claim 1 wherein said one or more hydrophobic adhesive polymers comprises acrylic polymers.

6. The transdermal delivery system of claim 1 comprising from about 3% to 35% by weight of said therapeutically effective amount of one or more drugs.

7. The transdermal delivery system of claim 4 wherein said drug comprises selegiline.

8. The transdermal delivery system of claim 7 including from about 3% to 18% by weight of said selegiline.

9. A transdermal delivery system comprising a blend of

(a) one or more hydrophobic acrylic adhesive polymers and one or more secondary adhesive polymers; and

(b) a therapeutically effective amount of one or more drugs, at least one of which is of low molecular weight and liquid at or about room temperature,

said system comprising a solvent system consisting essentially of at least one solvent which volatilizes during drying of said transdermal delivery system at temperatures of from about 100° F. to 200° F.

10. The transdermal delivery system of claim 9 wherein said one or more secondary adhesive polymers is selected from the group consisting of silicones, polyisoalkylenes, rubbers, vinyl acetates, polyisobutylenes, polybutadiene, styrene-butadiene (or isoprene)-styrene block copolymer rubber, acrylic rubber, natural rubber, vinyl-based high molecular weight materials, polyvinyl acetate, polyvinyl alcohol, polyvinyl pyrrolidone; cellulose derivatives, polysaccharides, polyurethane elastomers and polyester elastomers.

11. The transdermal delivery system of claim 10 wherein said one or more secondary adhesive polymers is selected from the group consisting of polyisobutylenes and silicones.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 14/303,531(INCORRECT) TO 14/303,831 (CORRECT) PREVIOUSLY RECORDED ON REEL 033512 FRAME 0071. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 3, 2014
From: GOVIL, SHARAD K.; WEIMANN, LUDWIG J.
To: BERTEK, INC.
Reel/Frame 033678/0280 →
CHANGE OF NAME Recorded Aug 13, 2014
From: BERTEK, INC.
To: MYLAN TECHNOLOGIES, INC.
Reel/Frame 033524/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2014
From: GOVIL, SHARAD K.; WEIMANN, LUDWIG J.
To: BERTEK, INC.
Reel/Frame 033512/0071 →
PATENT RELEASE Recorded Dec 10, 2012
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: DEY PHARMA L.P. (F/K/A DEY, L.P.); MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; SOMERSET PHARMACEUTICALS, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); MYLAN INC.
Reel/Frame 029440/0967 →